Minerva Neurosciences (NERV) Operating Expenses (2013 - 2026)

Minerva Neurosciences' Operating Expenses history runs 14 years deep, the most recent figure standing at $16.7 million for Q1 2026.

• Quarterly Operating Expenses rose 327.16% year-over-year to $16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.9 million (up 46.16% YoY) and the FY2025 annual result came in at $15.1 million, down 30.87% from the prior year.
• Operating Expenses was $16.7 million for Q1 2026 at Minerva Neurosciences, up from $5.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $16.7 million in Q1 2026 and bottomed at $2.8 million in Q3 2025.
• A 5-year average of $6.0 million and a median of $5.2 million in 2022 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses plunged 76.28% — and 2026, when it surged 327.16%.
• Minerva Neurosciences' Operating Expenses stood at $5.1 million in 2022, then soared by 41.47% to $7.2 million in 2023, then sank by 36.95% to $4.5 million in 2024, then grew by 10.16% to $5.0 million in 2025, then surged by 234.66% to $16.7 million in 2026.
• Business Quant data shows NERV's Operating Expenses at $16.7 million in Q1 2026, $5.0 million in Q4 2025, and $2.8 million in Q3 2025.